Clinical trials: in Moldova
Peritonitis, Intoxication
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis
This study evaluates the efficacy and safety of Rheosorbilact®, solution for infusion ("Yuria-Pharm" LLC), in comparison with Ringer's Lactate, solution for infusion, in a complex therapy of peritonitis.
- Trial name
- NCT03771170
- Testing
- Rheosorbilact®, Ringer lactate
- Where
- 10 sites in Georgia, Moldova and 2 more
- Volunteers
- 180 people
- Sponsor
- Yuria-Pharm
Pneumonia
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia
This study evaluates the efficacy and safety of Rheosorbilact®, solution for infusion ("Yuria-Pharm" LLC), in comparison with Ringer's Lactate, solution for infusion, in a complex therapy of pneumonia.
- Trial name
- NCT03824457
- Testing
- Rheosorbilact®, Ringer lactate
- Where
- 12 sites in Georgia, Kazakhstan and 4 more
- Volunteers
- 150 people
- Sponsor
- Yuria-Pharm
Chronic Hepatitis C, Hepatitis C
Study of AT-527 in Healthy and HCV-Infected Subjects
This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV).
- Conditions
- Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic
- Trial name
- NCT03219957
- Testing
- AT-527
- Where
- 2 sites in Belgium, Moldova
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Ulcerative Colitis
A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the safety and tolerability of PRV-300 for 12 weeks in subjects with active ulcerative colitis. Subjects will receive either PRV-300 or placebo treatment.
- Trial name
- PULSE (NCT03849599)
- Testing
- PRV-300
- Where
- 3 sites in Georgia, Moldova and 1 more
- Volunteers
- 37 people
- Sponsor
- Provention Bio, Inc.
Ulcerative Colitis
GB004 in Adult Subjects With Active Ulcerative Colitis
This is a Phase 1b, randomized, double-blind-, placebo-controlled, multi-center study to evaluate the safety, tolerability, and PK of GB004 in adult subjects with active ulcerative colitis.
- Trial name
- NCT03860896
- Testing
- GB004
- Where
- 3 sites in United States, Georgia and 1 more
- Volunteers
- 34 people
- Sponsor
- GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis…
- Trial name
- EXTEND (NCT01797965)
- Testing
- BIIB019 (Daclizumab)
- Where
- 222 sites in United States, Argentina and 25 more
- Volunteers
- 1,501 people
- Sponsor
- Biogen
Ovarian Neoplasms
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Anetumab ravtansine is developed for the treatment of patients with recurrent platinum-resistant ovarian cancer. The purpose of the proposed trial is to identify the maximum tolerated dose of anetumab ravtansine that could be…
- Trial name
- NCT02751918
- Testing
- Anetumab ravtansine (BAY94-9343), Pegylated Liposomal Doxorubicin
- Where
- 9 sites in United States, Belgium and 2 more
- Volunteers
- 65 people
- Sponsor
- Bayer
Cancer, Chronic Pain
Tapentadol in Chronic Malignant Tumour Related Pain
The purpose of this trial is the characterization of the long term safety profile and long-term dose requirements of tapentadol PR (prolonged release) in patients with malignant tumor-related pain.
- Conditions
- Cancer, Chronic Pain, Pain
- Trial name
- NCT01264887
- Testing
- Tapentadol Prolonged Release
- Where
- 12 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 31 people
- Sponsor
- Grünenthal GmbH
Tumor, Pain
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
- Trial name
- NCT00472303
- Testing
- Tapentadol Extended Release, Morphine Sulphate Controlled Release
- Where
- 71 sites in Austria, Bulgaria and 14 more
- Volunteers
- 622 people
- Sponsor
- Grünenthal GmbH
Renal Insufficiency, Healthy Volunteers
Pharmacokinetics, Dialysability and Safety of P03277 in Healthy Volunteers and in Patients With Impaired Renal Function
This is an open-label, non-randomized, successive cohorts design, multicenter, single dose phase I study. The primary objectives are: to evaluate the pharmacokinetics (plasma and urine) profile of P03277 following single…
- Trial name
- NCT03657784
- Testing
- P03277
- Where
- 2 sites in Moldova, Romania
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Guerbet
Chronic Hepatitis C
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered AL-335 in healthy volunteers (HV) and subjects with CHC infection.
- Trial name
- NCT02339207
- Testing
- AL-335
- Where
- 3 sites in France, Georgia and 1 more
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Chronic Hepatitis B
REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection
NAPs have been previously shown to clear serum hepatitis B virus surface antigen (HBsAg) both preclinically (in duck HBV infected ducks) and in human patients.
- Trial name
- NCT02565719
- Testing
- REP 2139-Mg, Pegasys, Viread
- Where
- 3 sites in Moldova
- Volunteers
- 40 people
- Sponsor
- Replicor Inc.
Rheumatoid Arthritis
A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis
The primary objective of this study is: To assess the efficacy and safety of dose regimens of ALX-0061 monotherapy administered subcutaneously (s.c.) to subjects with active rheumatoid arthritis (RA).
- Trial name
- NCT02287922
- Testing
- ALX-0061, Tocilizumab
- Where
- 83 sites in United States, Belgium and 12 more
- Volunteers
- 251 people
- Sponsor
- Ablynx, a Sanofi company
Rheumatoid Arthritis
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
The purpose of this study is to assess the efficacy and safety of dose regimens of ALX-0061 administered subcutaneously (s.c.) in combination with methotrexate (MTX) to subjects with active rheumatoid arthritis (RA) despite MTX…
- Trial name
- NCT02309359
- Testing
- ALX-0061, Methotrexate
- Where
- 94 sites in United States, Belgium and 12 more
- Volunteers
- 345 people
- Sponsor
- Ablynx, a Sanofi company
Rheumatoid Arthritis
Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT03139136
- Testing
- MBS2320
- Where
- 3 sites in Georgia, Moldova and 1 more
- Volunteers
- 121 people
- Sponsor
- Modern Biosciences Ltd
Rheumatoid Arthritis
An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis
This was a multicenter, open-label extension (OLE) Phase II study designed to evaluate the long-term efficacy and safety of ALX-0061 (i.e., vobarilizumab) administered subcutaneously (s.c.) in subjects with active rheumatoid…
- Trial name
- NCT02518620
- Testing
- ALX-0061
- Where
- 57 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 406 people
- Sponsor
- Ablynx, a Sanofi company
Chronic Hepatitis C
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
The purpose of this study is to evaluate the safety and tolerability of AL-335 in combination with odalasvir (ODV) with or without simeprevir (SMV) in participants with genotype (GT)1 or GT2 or GT3 chronic hepatitis C (CHC)…
- Trial name
- NCT02569710
- Testing
- AL-335, Odalasvir (ODV), Simeprevir (SMV)
- Where
- 11 sites in Mauritius, Moldova and 2 more
- Volunteers
- 161 people
- Sponsor
- Alios Biopharma Inc.
Immune Thrombocytopenic Purpura
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
- Trial name
- ITP (NCT02273960)
- Testing
- BMS-986004 75 mg IV, BMS-986004 225 mg IV, BMS-986004 675 mg IV
- Where
- 20 sites in United States, Australia and 6 more
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Post Herpetic Neuralgia, Diabetic Peripheral Neuropathy
Titration Study of ABX-1431
This study is designed to identify a titration regimen of ABX-1431 in adults with neuropathic pain with satisfactory tolerability to central nervous system (CNS) adverse events (AEs).
- Conditions
- Post Herpetic Neuralgia, Diabetic Peripheral Neuropathy, Small Fiber Neuropathy, Post-Traumatic Neuralgia
- Trial name
- NCT03447756
- Testing
- ABX-1431
- Where
- Moldova
- Volunteers
- 39 people
- Sponsor
- Abide Therapeutics
Osteoarthritis, Knee
A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients
This is a multicentre, randomised, placebo-controlled, double-blind, three-arm parallel, Phase IIa study to evaluate the efficacy, safety and tolerability of MIV-711 in patients with knee osteoarthritis (OA).
- Trial name
- NCT02705625
- Testing
- MIV-711
- Where
- 6 sites in Bulgaria, Georgia and 4 more
- Volunteers
- 244 people
- Sponsor
- Medivir